Targeting Paclitaxel-Loaded Nanoparticles to Ovarian Cancer
Abstract
The specific aims of this project are to: (1) determine the efficacy, pharmacokinetics, toxicology and imaging capacity of RGD-targeted Nexil; and, (2) determine the ability of other ovarian cancer-specific targeting ligands to enhance the efficacy of Nexil. Substantial progress has been made on both of these specific aims. This progress report covers work done during the first 10 months of the grant. Significant achievements to date include: the design and synthesis of two different linkers to be used in the coupling with the RGD peptide to the Nexil polymer; the synthesis of cyclic RGD peptide usign Fmoc strategy on solid support; the coupling of cyclic RGD to linkers, deprotection and documentation of purity; synthesis of a set of molecules containing 5, 15 and 30 RGD units per polyglutamylglutamate molecule; establishment of a fluorescence polarization assay for assessment of affinity of binding to soluble integrins; addition of a fluorochrome to RGD-linker polymer to facilitate pharmacokinetic and tissue distribution studies; and, establishment of a strategy for the synthesis of Lyp-1 using a solid support strategy.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2011
- Accession Number
- ADA548106
Entities
People
- Stephen Howell
Organizations
- University of California, San Diego